Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aleix Prat

Showing results (71-80 of 326) with videos related to

Pageof 33
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2021
Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III StudiesAleix Prat, Anwesha Chaudhury, Nadia Solovieff, et al.
Breast (Edinburgh, Scotland)|May 21, 2024
"Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper"Pierfranco Conte, Eva Ciruelos, Giuseppe Curigliano, et al.
ESMO Open|November 16, 2016
Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritisFrancisco Aya, Lydia Gaba, Ivan Victoria, et al.
Clinical & Experimental Metastasis|August 27, 2013
Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasisJ Chuck Harrell, Adam D Pfefferle, Nicole Zalles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2024
Computational Model Predicts Patient Outcomes in Luminal B Breast Cancer Treated with Endocrine Therapy and CDK4/6 InhibitionLeonard Schmiester, Fara Brasó-Maristany, Blanca González-Farré, et al.
Plos One|September 25, 2025
Latent representation of H&E images retains biological information in a breast cancer cohortChloé Benmussa, Esther Sanfeliu, Anabel Martínez-Romero, et al.
Breast (Edinburgh, Scotland)|September 23, 2023
Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8Guy Jerusalem, Aleix Prat, Roberto Salgado, et al.
Breast Cancer Research : BCR|January 11, 2023
Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)Sanne L de Haas, Dennis J Slamon, Miguel Martin, et al.
JAMA Oncology|June 10, 2016
Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without LapatinibAleix Prat, Maggie C U Cheang, Patricia Galván, et al.
Molecular and Cellular Biology|May 30, 2013
SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c controls epithelial-mesenchymal transition by inducing Wnt5a signalingNicole Vincent Jordan, Aleix Prat, Amy N Abell, et al.
Pageof 33

Showing results (71-80 of 326) with videos related to

Sort By:
Pageof 33
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2021
Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III StudiesAleix Prat, Anwesha Chaudhury, Nadia Solovieff, et al.
Breast (Edinburgh, Scotland)|May 21, 2024
"Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper"Pierfranco Conte, Eva Ciruelos, Giuseppe Curigliano, et al.
ESMO Open|November 16, 2016
Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritisFrancisco Aya, Lydia Gaba, Ivan Victoria, et al.
Clinical & Experimental Metastasis|August 27, 2013
Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasisJ Chuck Harrell, Adam D Pfefferle, Nicole Zalles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2024
Computational Model Predicts Patient Outcomes in Luminal B Breast Cancer Treated with Endocrine Therapy and CDK4/6 InhibitionLeonard Schmiester, Fara Brasó-Maristany, Blanca González-Farré, et al.
Plos One|September 25, 2025
Latent representation of H&E images retains biological information in a breast cancer cohortChloé Benmussa, Esther Sanfeliu, Anabel Martínez-Romero, et al.
Breast (Edinburgh, Scotland)|September 23, 2023
Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8Guy Jerusalem, Aleix Prat, Roberto Salgado, et al.
Breast Cancer Research : BCR|January 11, 2023
Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)Sanne L de Haas, Dennis J Slamon, Miguel Martin, et al.
JAMA Oncology|June 10, 2016
Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without LapatinibAleix Prat, Maggie C U Cheang, Patricia Galván, et al.
Molecular and Cellular Biology|May 30, 2013
SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c controls epithelial-mesenchymal transition by inducing Wnt5a signalingNicole Vincent Jordan, Aleix Prat, Amy N Abell, et al.
Pageof 33